Latest Breaking News On - Andreas kranzusch - Page 1 : vimarsana.com

Allecra Therapeutics Announces U S FDA Approval for EXBLIFEP for the Treatment of Complicated Urinary Tract Infections

Allecra Therapeutics Announces U S FDA Approval for EXBLIFEP for the Treatment of Complicated Urinary Tract Infections
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Edward currieIain buchananPatrick velicitatAdvanz pharmaBeta lactamasesOmar lahlouAndreas kranzuschNicholas benedictDesmond jamesStuart shapiroUs congressEuropean medicines agencyDrug administrationCompany receives exclusivity extension throughPharmaceuticals ltdTrophic communications

Allecra Therapeutics Submits New Drug Application to the U S FDA for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections

Allecra Therapeutics Submits New Drug Application to the U S FDA for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Beta lactamasesDesmond jamesAndreas kranzuschIain buchananAdvanz pharmaTrophic communicationsDrug administrationEuropean medicines agencyNew drug applicationExtended spectrum beta lactamasesSupervisory board memberQualified infectious disease productMarketing authorization approvalAndera partnersDelos capitalXeraya capital

Allecra Therapeutics Submits New Drug Application to the U S FDA for EXBLIFEP for the Treatment of Complicated Urinary Tract Infections

Allecra Therapeutics Submits New Drug Application to the U S FDA for EXBLIFEP for the Treatment of Complicated Urinary Tract Infections
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Advanz pharmaIain buchananDesmond jamesAndreas kranzuschBeta lactamasesDrug administrationEuropean medicines agencyTrophic communicationsAllecra therapeuticsNew drug applicationExtended spectrum beta lactamasesSupervisory board memberQualified infectious disease productMarketing authorization approvalAndera partnersDelos capital

Allecra Therapeutics Publishes Final Phase 3 ALLIUM Data in JAMA: Cefepime/Enmetazobactam Met Criteria for Superiority

Allecra Therapeutics ("Allecra") announced today that the final results from its Phase 3 ALLIUM trial investigating the combination of cefepime/enmetazobactam in patients with complicated urinary tract

South africaUnited statesUnited kingdomPatrick velicitatAndreas kranzuschKeith kayeBeta lactamases esblsDivision of allergyDrug administrationJournal of the american medical associationRobert wood johnson medical school rutgers universityEuropean unionEuropean medicines agencyAllecra therapeuticsAmerican medical associationExtended spectrum beta lactamases

Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China – IT Business Net

Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties Shanghai Haini gains exclusive manufacturing, development and commercial rights for the licensed territory SAINT-LOUIS, France and WEIL AM RHEIN, Germany and SHANGHAI, China, Dec. 21, 2020 (GLOBE NEWSWIRE) Shanghai Haini Pharmaceutical Co., Ltd. (Shanghai Haini), the subsidiary of Yangtze River Pharmaceutical Group (YRPG), and Allecra Therapeutics (Allecra) today announced that the companies have signed an exclusive licensing agreement under which Shanghai Haini will manufacture, develop and commercialize cefepime/enmetazobactam within Greater

Yangtze riverChina generalHong kongAndreas kranzuschIain buchananJulia braunLaurie doyleRaimund gabrielMc servicesDrug administrationBaker mckenzieStaatz business development strategyShanghai haini pharmaceutical co ltdYangtze river pharmaceutical groupEuropean medicines agencyExclusive licensing agreement